Dark Horse Consulting Group (DHCG) has announced its acquisition of Bruder Consulting & Venture Group (BCVG), a strategic advisory firm specializing in biotechnology and biopharma. This acquisition, effective as of January 9, 2026, marks a significant step for DHCG as it integrates BCVG into its operations, establishing a new department called DHC Regenerative Medicine.
With its expertise in the discovery, development, clinical design, and regulatory approval of biologics and medical devices, BCVG brings a wealth of knowledge to DHCG. The firm has established a strong presence in the orthopedic, wound care, and plastic and reconstructive surgery markets. This addition aligns with DHCG’s ongoing commitment to enhancing patient outcomes through biotherapeutics.
The acquisition not only expands DHCG’s range of consulting services but also reinforces its position as a fully integrated global consulting practice. This move follows recent expansions with BioTechLogic and Converge Consulting, allowing DHCG to offer comprehensive services in regenerative medicine, tissue repair, and biomaterials.
Strengthening Capabilities and Expertise
Anthony Davies, Ph.D., Founder and CEO of Dark Horse Consulting Group, expressed enthusiasm about the acquisition, stating, “Welcoming Bruder into the Dark Horse family as our experts in Regenerative Medicine marks yet another meaningful milestone in our period of strategic growth.” He emphasized that BCVG’s experience enriches DHCG’s capabilities, ultimately benefiting clients and patients worldwide.
Scott P. Bruder, M.D., Ph.D., Founder and CEO of BCVG, highlighted the advantages of joining forces with DHCG, stating, “Joining forces with DHCG allows us to scale the expertise that our core team and advisors can provide.” He noted that this partnership would enhance the services available to clients at every stage of the development process.
This acquisition is also notable in terms of its financial implications. BCVG has successfully completed over 900 projects for more than 150 companies globally and has been involved in transactions exceeding $2 billion related to licensing, mergers, and acquisitions in the biopharma sector.
About the Consulting Firms
Dark Horse Consulting Group operates globally with offices across North America, Europe, and the Asia-Pacific region. Founded in 2014, DHCG originally focused on accelerating the development of cell and gene therapies. Over time, it has broadened its service offerings, now encompassing various areas such as strategy, operations, regulatory affairs, and business optimization.
Bruder Consulting & Venture Group has built a reputation for its comprehensive advisory services in the biopharmaceutical space. The firm’s deep industry knowledge and experience in navigating regulatory processes position it as a valuable asset within the Dark Horse ecosystem.
As the consulting landscape continues to evolve, the integration of Bruder Consulting into Dark Horse Consulting Group underscores a strategic commitment to delivering enhanced solutions in the biopharmaceutical industry. The partnership aims to accelerate therapy development, ultimately improving patient outcomes on a global scale.
For media inquiries, contact DHCG at [email protected] or call +1 408-326-0303 ext. 209.
